Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | MAP2K1 E203K PIK3CA amp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
MAP2K1 E203K PIK3CA amp | skin squamous cell carcinoma | predicted - sensitive | Metformin + Trametinib | Case Reports/Case Series | Actionable | In a clinical case study, a combination of Glucophage (metformin) and Mekinist (trametinib) resulted in a complete clinical response and continued remission for over two years in a patient with cutaneous squamous cell carcinoma with amplification of PIK3CA and harboring MAP2K1 E203K (PMID: 35005996). | 35005996 |